{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:35:48Z","timestamp":1789983348866,"version":"4.0.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.remnie.2024.500017","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:43:55Z","timestamp":1715355835000},"page":"500017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Radio theranostics in paragangliomas and pheochromocytomas"],"prefix":"10.1016","volume":"43","author":[{"given":"Stefan","family":"Prado Wohlwend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Bello Arques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.remnie.2024.500017_bib0005","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00259-012-2215-8","article-title":"EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"39","author":"Taieb","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0010","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an Endocrine Society Clinical Practice Guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/his.13402","article-title":"Pathology and genetics of phaeochromocytoma and paraganglioma","volume":"72","author":"Turchini","year":"2018","journal-title":"Histopathology."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0020","doi-asserted-by":"crossref","first-page":"e1937","DOI":"10.1210\/clinem\/dgaa982","article-title":"Metastatic pheochromocytomas and abdominal paragangliomas","volume":"106","author":"Granberg","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.MP.0000056982.07160.E3","article-title":"KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma","volume":"16","author":"Elder","year":"2003","journal-title":"Mod Pathol."},{"issue":"8","key":"10.1016\/j.remnie.2024.500017_bib0030","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8898","article-title":"Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy","volume":"2","author":"Neumann","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40618-020-01344-z","article-title":"Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview","volume":"44","author":"De Filpo","year":"2021","journal-title":"J Endocrinol Invest."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0040","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0045","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1210\/jc.2018-01968","article-title":"Prognosis of malignant pheochromocytoma and paraganglioma (MAPP-Prono Study): a European Network for the Study of Adrenal Tumors Retrospective Study","volume":"104","author":"Hescot","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.trecan.2017.11.001","article-title":"Genomic landscape of pheochromocytoma and paraganglioma","volume":"4","author":"Jochmanova","year":"2018","journal-title":"Trends Cancer."},{"issue":"11","key":"10.1016\/j.remnie.2024.500017_bib0055","doi-asserted-by":"crossref","first-page":"R627","DOI":"10.1530\/ERC-19-0165","article-title":"Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups","volume":"26","author":"Ta\u00efeb","year":"2019","journal-title":"Endocr Relat Cancer."},{"issue":"10","key":"10.1016\/j.remnie.2024.500017_bib0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.3390\/cancers11101505","article-title":"Current management of pheochromocytoma\/paraganglioma: a guide for the practicing clinician in the era of precision medicine","volume":"11","author":"N\u00f6lting","year":"2019","journal-title":"Cancers."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0065","doi-asserted-by":"crossref","first-page":"684","DOI":"10.2214\/ajr.185.3.01850684","article-title":"Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas","volume":"185","author":"Motta-Ramirez","year":"2005","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.remnie.2024.500017_bib0070","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1148\/rg.24si045506","article-title":"Pheochromocytoma: an imaging chameleon","author":"Blake","year":"2004","journal-title":"Radiographics."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0075","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0936-6555(02)00273-X","article-title":"Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy","volume":"15","author":"Bomanji","year":"2003","journal-title":"Clin Oncol."},{"issue":"12","key":"10.1016\/j.remnie.2024.500017_bib0080","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/diagnostics10121083","article-title":"The challenge of evaluating response to peptide receptor radionuclide therapy in gastroenteropancreatic neuroendocrine tumors: the present and the future","volume":"10","author":"Liberini","year":"2020","journal-title":"Diagnostics."},{"issue":"8","key":"10.1016\/j.remnie.2024.500017_bib0085","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12149-018-1291-7","article-title":"Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications","volume":"32","author":"Werner","year":"2018","journal-title":"Ann Nucl Med."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0090","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1210\/jc.2012-2975","article-title":"Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA investigators","volume":"98","author":"Gimenez-Roqueplo","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2967\/jnumed.118.211706","article-title":"Performance of 68 Ga-DOTA\u2013conjugated somatostatin receptor\u2013targeting peptide PET in detection of pheochromocytoma and paraganglioma: a systematic review and metaanalysis","volume":"60","author":"Han","year":"2019","journal-title":"J Nucl Med."},{"issue":"2","key":"10.1016\/j.remnie.2024.500017_bib0100","doi-asserted-by":"crossref","first-page":"186","DOI":"10.2967\/jnumed.115.161018","article-title":"68Ga-DOTATATE PET\/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT\/MRI","volume":"57","author":"Janssen","year":"2016","journal-title":"J Nucl Med."},{"issue":"9","key":"10.1016\/j.remnie.2024.500017_bib0105","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1210\/jc.2017-00816","article-title":"Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma","volume":"102","author":"Kong","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0110","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2006-2315","article-title":"Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas","volume":"92","author":"Timmers","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"10.1016\/j.remnie.2024.500017_bib0115","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/MNM.0000000000000008","article-title":"Normal biodistribution pattern and physiologic variants of 18F-DOPA PET imaging","volume":"34","author":"Chondrogiannis","year":"2013","journal-title":"Nucl Med Commun."},{"issue":"7","key":"10.1016\/j.remnie.2024.500017_bib0120","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00259-012-2087-y","article-title":"Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis","volume":"39","author":"Treglia","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"10.1016\/j.remnie.2024.500017_bib0125","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12149-019-01378-1","article-title":"Limited role of carbidopa-assisted 18F-FDOPA PET\/CT in patients with sporadic non-functional gastroduodenal neuroendocrine neoplasms","volume":"33","author":"Imperiale","year":"2019","journal-title":"Ann Nucl Med."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0130","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.surg.2006.07.039","article-title":"Posterior retroperitoneoscopic adrenalectomy-results of 560 procedures in 520 patients","volume":"140","author":"Walz","year":"2006","journal-title":"Surgery."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0194599815627667","article-title":"Head and neck paragangliomas: an update on evaluation and management","volume":"154","author":"Moore","year":"2016","journal-title":"Otolaryngol Head Neck Surg."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0140","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","article-title":"Impact of surgical resection of the primary tumor on overall survival in patients with metastatic pheochromocytoma or sympathetic paraganglioma","volume":"268","author":"Roman-Gonzalez","year":"2018","journal-title":"Ann Surg."},{"issue":"13","key":"10.1016\/j.remnie.2024.500017_bib0145","doi-asserted-by":"crossref","first-page":"R150","DOI":"10.1088\/0031-9155\/61\/13\/R150","article-title":"Applications and limitations of radiomics","volume":"61","author":"Yip","year":"2016","journal-title":"Phys Med Biol."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0150","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1210\/er.2017-00062","article-title":"New perspectives on pheochromocytoma and paraganglioma: toward a molecular classification","volume":"38","author":"Crona","year":"2017","journal-title":"Endocrine Rev."},{"issue":"11","key":"10.1016\/j.remnie.2024.500017_bib0155","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1158\/1078-0432.CCR-20-3703","article-title":"High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Jha","year":"2021","journal-title":"Clin Cancer Res."},{"issue":"11","key":"10.1016\/j.remnie.2024.500017_bib0160","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","article-title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMOeEURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Fassnacht","year":"2020","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.remnie.2024.500017_bib0165","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13139-015-0331-7","article-title":"Diagnostic performance of 68Ga-DOTATATE PET\/CT, 18F-FDG PET\/CT and 131I-MIBG scintigraphy in mapping metastatic pheochromocytoma and paraganglioma","volume":"49","author":"Tan","year":"2015","journal-title":"Nucl Med Mol Imaging."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0170","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s00259-008-0715-3","article-title":"EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy","volume":"35","author":"Giammarile","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"7","key":"10.1016\/j.remnie.2024.500017_bib0175","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.3390\/jcm9072203","article-title":"Prevention and management of hormonal crisis during theragnosis with LU-DOTA-TATE in neuroendocrine tumors. A systematic review and approach proposal","volume":"9","author":"del Olmo-Garc\u00eda","year":"2020","journal-title":"J Clin Med."},{"issue":"7","key":"10.1016\/j.remnie.2024.500017_bib0180","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.3390\/cancers11071018","article-title":"Targeted radionuclide therapy for patients with metastatic pheochromocytoma and paraganglioma: from low-specific-activity to high-specific-activity iodine-131 metaiodobenzylguanidine","volume":"11","author":"Jimenez","year":"2019","journal-title":"Cancers."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0185","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00259-007-0652-6","article-title":"[131]I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma","volume":"35","author":"Gedik","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0190","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/COC.0b013e31819e2c28","article-title":"Low-dose iodine-131 metaiodobenzylguanidine therapy for patients with malignant pheochromocytoma and paraganglioma single center experience","volume":"33","author":"Shilkrut","year":"2010","journal-title":"Am J Clin Oncol."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0195","doi-asserted-by":"crossref","first-page":"7625","DOI":"10.1038\/s41598-019-43880-6","article-title":"A phase I clinical trial for [131I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma","volume":"9","author":"Wakabayashi","year":"2019","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0200","first-page":"100","article-title":"(131)I-MIBG treatment of pheochromocytoma: low versus intermediate activity regimens of therapy","volume":"54","author":"Castellani","year":"2010","journal-title":"Q J Nucl Med Mol Imaging."},{"issue":"25","key":"10.1016\/j.remnie.2024.500017_bib0205","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2008.21.3496","article-title":"Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma","volume":"27","author":"Gonias","year":"2009","journal-title":"J Clin Oncol."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0210","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cen.12341","article-title":"131I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis","volume":"80","author":"Van Hulsteijn","year":"2013","journal-title":"Clin Endocrinol."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0215","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s13139-018-0517-x","article-title":"Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives","volume":"52","author":"Hirmas","year":"2018","journal-title":"Nucl Med Mol Imaging."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0220","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.semnuclmed.2020.05.004","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors","volume":"50","author":"Basu","year":"2020","journal-title":"Semin Nucl Med."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0225","first-page":"406","article-title":"Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC","volume":"22","author":"Wehrmann","year":"2007","journal-title":"Cancer Biother Radiopharm."},{"issue":"2","key":"10.1016\/j.remnie.2024.500017_bib0230","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2214\/AJR.18.19953","article-title":"Neuroendocrine tumor therapy: 177Lu-DOTATATE","volume":"211","author":"Mittra","year":"2018","journal-title":"AJR Am J Roentgenol."},{"key":"10.1016\/j.remnie.2024.500017_bib0235","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-023-06166-8","article-title":"Efficacy of [ 177 Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study","author":"Mitjavila","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0240","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/cen.14106","article-title":"Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis","volume":"91","author":"Satapathy","year":"2019","journal-title":"Clin Endocrinol."},{"key":"10.1016\/j.remnie.2024.500017_bib0245","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.778322","article-title":"[177Lu]Lu-DOTA-TATE and [131I]MIBG phenotypic imaging-based therapy in metastatic\/inoperable pheochromocytomas and paragangliomas: comparative results in a single center","author":"Prado-Wohlwend","year":"2022","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.remnie.2024.500017_bib0250","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.957172","article-title":"Response to targeted radionuclide therapy with [131I]MIBG AND [177Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review","author":"Prado-Wohlwend","year":"2022","journal-title":"Front Endocrinol."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0255","doi-asserted-by":"crossref","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","article-title":"NCCN guidelines insights: neuroendocrine and adrenal tumors, Version 2.2018","volume":"16","author":"Shah","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"issue":"05","key":"10.1016\/j.remnie.2024.500017_bib0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1055\/s-0032-1308992","article-title":"External Beam Radiation Therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG","volume":"44","author":"Fishbein","year":"2012","journal-title":"Horm Metab Res."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0265","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera\u00ae orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics."},{"issue":"4","key":"10.1016\/j.remnie.2024.500017_bib0270","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.bbmt.2014.12.008","article-title":"131I-Metaiodobenzylguanidine with intensive chemotherapy and autologous stem cell transplantation for high-risk neuroblastoma. A new approaches to neuroblastoma therapy (NANT) phase II study","volume":"21","author":"Yanik","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.remnie.2024.500017_bib0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13550-019-0484-y","article-title":"Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas","volume":"9","author":"Yadav","year":"2019","journal-title":"EJNMMI Res."},{"issue":"12","key":"10.1016\/j.remnie.2024.500017_bib0280","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11912-017-0643-0","article-title":"Treatment for malignant pheochromocytomas and paragangliomas: 5 years of progress","volume":"19","author":"Jimenez","year":"2017","journal-title":"Curr Oncol Rep."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0285","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med."},{"issue":"6","key":"10.1016\/j.remnie.2024.500017_bib0290","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00259-017-3919-6","article-title":"Antitumor effects of radionuclide treatment using \u03b1-emitting meta-211At-astato-benzylguanidine in a PC12 pheochromocytoma model","volume":"45","author":"Ohshima","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"3","key":"10.1016\/j.remnie.2024.500017_bib0295","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/1874471011666180502104524","article-title":"An overview of targeted alpha therapy with 225Actinium and 213Bismuth","volume":"11","author":"Morgenstern","year":"2018","journal-title":"Curr Radiopharm."},{"issue":"5","key":"10.1016\/j.remnie.2024.500017_bib0300","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of 225Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253808924000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T01:40:32Z","timestamp":1722908432000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253808924000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2253808924000338"],"URL":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500017","relation":{},"ISSN":["2253-8089"],"issn-type":[{"value":"2253-8089","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radio theranostics in paragangliomas and pheochromocytomas","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remnie.2024.500017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"500017"}}